Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Stock analysts at Zacks Research increased their Q3 2026 earnings estimates for shares of Prestige Consumer Healthcare in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.25 per share for the quarter, up from their prior forecast of $1.24. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.50 per share.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%.
Several other equities research analysts also recently weighed in on the stock. Canaccord Genuity Group raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, February 7th. StockNews.com raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Friday, January 24th. Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. Finally, DA Davidson lifted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $92.60.
Check Out Our Latest Stock Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare Trading Up 0.9 %
Prestige Consumer Healthcare stock traded up $0.79 during mid-day trading on Monday, reaching $86.27. 89,334 shares of the company traded hands, compared to its average volume of 315,350. The firm's 50 day moving average price is $80.43 and its 200 day moving average price is $77.57. The firm has a market capitalization of $4.27 billion, a price-to-earnings ratio of 20.20, a P/E/G ratio of 2.69 and a beta of 0.50. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. Prestige Consumer Healthcare has a 52-week low of $62.35 and a 52-week high of $88.36.
Institutional Investors Weigh In On Prestige Consumer Healthcare
Hedge funds have recently bought and sold shares of the stock. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Prestige Consumer Healthcare in the 4th quarter valued at $7,778,000. Kayne Anderson Rudnick Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the 4th quarter worth approximately $84,932,000. Vise Technologies Inc. acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at about $319,000. McIlrath & Eck LLC grew its stake in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Prestige Consumer Healthcare by 24.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 118,113 shares of the company's stock valued at $9,223,000 after purchasing an additional 23,334 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.
About Prestige Consumer Healthcare
(
Get Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Recommended Stories
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
